| Literature DB >> 31533647 |
Xianghong Zhang1,2, Qiong Lu3, Tang Liu4, Zhihong Li1, Weiliang Cai5.
Abstract
BACKGROUND: The purpose of this study was to gather temporal trends on bacteria epidemiology and resistance of intraoperative bone culture from chronic ostemyelitis at an affiliated hospital in South China.Entities:
Keywords: Bacterial culture positive rate; Chronic osteomyelitis; Intra-operative bone culture; Long-term secular trends, antibiotic resistance
Mesh:
Substances:
Year: 2019 PMID: 31533647 PMCID: PMC6751654 DOI: 10.1186/s12879-019-4460-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Age-specific positive rate for intraoperative bone culture of chronic osteomyelites (2003–2014)
| Positive-rate(%) | |||
|---|---|---|---|
| Age group (yr) | < 18 | 18–44 | ≥45 |
| Year group (yr) | |||
| 2003–2004 | 25.0 | 46.4 | 41.2 |
| 2005–2006 | 55.6 | 49.1 | 61.9 |
| 2007–2008 | 60.0 | 68.1 | 66.7 |
| 2009–2010 | 75.0 | 70.0 | 62.5 |
| 2011–2012 | 80.0 | 80.0 | 78.2 |
| 2013–2014 | 66.7 | 70.1 | 67.8 |
| H value | 10.530 | 18.270 | 8.811 |
| 0.062 | 0.006* | 0.117 | |
*P < 0.05 statistically significant
Etiology-specific positive rate for intraoperative bone culture of chronic osteomyelites (2003–2014)
| Pathogenesis | Positive-rate(%) | |||
|---|---|---|---|---|
| traumatic | adjacent infection | hematogenic | others | |
| Year group | ||||
| 2003–2004 | 53.8 | 16.7 | 27.31 | 35.7 |
| 2005–2006 | 50.9 | 37.5 | 57.1 | 66.7 |
| 2007–2008 | 68.4 | 55.6 | 100.0 | 63.6 |
| 2009–2010 | 69.1 | 66.7 | 80.0 | 61.3 |
| 2011–2012 | 88.7 | 70.6 | 90.0 | 64.3 |
| 2013–2014 | 79.7 | 50.0 | 100.0 | 59.0 |
| H value | 28.081 | 6.900 | 16.686 | 4.191 |
| 0.000* | 0.228 | 0.005* | 0.522 | |
*P < 0.05 statistically significant
Fig. 1The pathogen distribution of chronic osteomyelitis from 2003 to 2014
Resistance rates(%) of Staphylococcus aureus to antimicrobial agents
| Antimicrobial agent | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 |
|---|---|---|---|---|---|---|
| Vancomycin | 0 | 0 | 0 | 0 | 2.9 | 0 |
| Linezolid | 0 | 0 | 0 | 6.3 | 2.9 | 0 |
| Teicoplanin | – | 0 | 0 | 0 | 0 | 0 |
| Rifampin | 40.0 | 12.5 | 0 | 10.0 | 25.0 | 20.0 |
| Levofloxacin | – | – | 0 | 43.8 | 54.3 | 33.3 |
| Ciprofloxacin | 0 | 41.7 | 10.0 | 26.7 | 25.7 | 30.0 |
| Gentamicin | 20.0 | 46.2 | 0 | 26.7 | 34.3 | 31.0 |
| Clindamycin | – | 36.4 | 10.0 | 30.8 | 62.9 | 44.8 |
| Erythromycin | 40.0 | 66.7 | 14.3 | 36.4 | 65.7 | 46.7 |
| Penicillin G | 33.3 | 100.0 | 81.8 | 87.5 | 94.3 | 88.0 |
| Ampicillin | – | 100.0 | 90.0 | 92.3 | 96.0 | 95.8 |
Resistance rates(%) of Pseudomonas aeruginosa to antimicrobial agents
| Antimicrobial agent | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 |
|---|---|---|---|---|---|---|
| Amikacin | 0 | 25.0 | 0 | 14.3 | 14.3 | 0 |
| Gentamicin | 0 | 25.0 | 33.3 | 42.9 | 28.6 | 13.3 |
| Piperacillin | 0 | 37.5 | 66.7 | 28.6 | 15.4 | 14.3 |
| Piperacillin/taazobactam | – | 20.0 | 66.7 | 28.6 | 21.4 | 0 |
| Cefazolin | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Cefuroxime | 100.0 | 100.0 | – | 100.0 | 100.0 | 100.0 |
| Cefotaxime | – | 100.0 | 0 | 75.0 | 100.0 | 100.0 |
| Ceftazidime | 0 | 12.5 | 66.7 | 14.3 | 14.3 | 6.7 |
| Cefepime | – | 0 | 0 | 28.6 | 14.3 | 0 |
| Cefoxitin | 100.0 | 100.0 | 100.0 | – | – | 100.0 |
| Imipenem | 0 | 0 | 33.3 | 14.3 | 7.7 | 6.7 |
| Meropenem | – | 0 | 50.0 | 66.7 | 27.3 | 0 |
| Ciprofloxacin | 0 | 37.5 | 0 | 14.3 | 21.4 | 13.3 |
Resistance rates(%) of Enterobacter cloacae to antimicrobial agents
| Antimicrobial agent | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 |
|---|---|---|---|---|---|---|
| Amikacin | 50.0 | 0 | 45.5 | 33.3 | 0 | 9.1 |
| Gentamicin | 50.0 | 100.0 | 66.7 | 66.7 | 66.7 | 45.5 |
| Piperacillin | 50.0 | 100.0 | 100.0 | 83.3 | 100.0 | 63.6 |
| Cefazolin | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Cefuroxime | 75.0 | 100.0 | 90.9 | 66.7 | 100.0 | 100.0 |
| Cefotaxime | – | 100.0 | 90.9 | 83.3 | 100.0 | 54.5 |
| Ceftazidime | 50.0 | 0 | 83.3 | 83.3 | 33.3 | 36.4 |
| Cefepime | 100.0 | 50.0 | 66.7 | 66.7 | 100.0 | 45.5 |
| Cefoperazone | 100.0 | 100.0 | 100.0 | – | – | 100.0 |
| Cefoxitin | 100.0 | 50.0 | 100.0 | – | – | 100.0 |
| Imipenem | 0 | 0 | 0 | 0 | 0 | 9.1 |
| Meropenem | 0 | 0 | 33.3 | – | – | 18.2 |
| Ciprofloxacin | 0 | 100.0 | 54.5 | 66.7 | 100.0 | 9.1 |
Resistance rates(%) of Acinetobacter baumanii to antimicrobial agents
| Antimicrobial agent | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 |
|---|---|---|---|---|---|---|
| Amikacin | – | 66.7 | 66.7 | 50.0 | 64.7 | 100.0 |
| Gentamicin | – | 100.0 | 100.0 | 75.0 | 82.4 | 100.0 |
| Piperacillin | – | 100.0 | 66.7 | 75.0 | 88.2 | 100.0 |
| Piperacillin/taazobactam | – | 100.0 | 100.0 | 75.0 | 88.2 | 100.0 |
| Cefazolin | – | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Cefuroxime | – | 100.0 | 100.0 | 100.0 | 100.0 | – |
| Cefotaxime | – | 100.0 | 80.0 | 75.0 | 82.4 | 100.0 |
| Ceftazidime | – | 100.0 | 60.0 | 50.0 | 76.5 | 50.0 |
| Cefepime | – | 100.0 | 100.0 | 50.0 | 70.6 | 50.0 |
| Imipenem | – | 33.3 | 16.7 | 50.0 | 64.7 | 100.0 |
| Meropenem | – | 100.0 | 0 | 80.0 | 75.0 | 100.0 |
| Ciprofloxacin | – | 100.0 | 83.3 | 62.5 | 70.6 | 100.0 |
Resistance rates(%) of Escherichia coli to antimicrobial agents
| Antimicrobial agent | 2003–2004 | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 |
|---|---|---|---|---|---|---|
| Amikacin | – | 25.0 | 0 | 14.3 | 25.0 | 0 |
| Gentamicin | – | 50.0 | 100.0 | 57.1 | 50.0 | 22.2 |
| Piperacillin | – | 100.0 | 100.0 | 100.0 | 87.5 | 88.9 |
| Cefazolin | – | 50.0 | 100.0 | 100.0 | 75.0 | 88.9 |
| Cefuroxime | – | 75.0 | 100.0 | 100.0 | 75.0 | 100.0 |
| cefotaxime | – | 25.0 | 100.0 | 100.0 | 75.0 | 77.8 |
| Ceftazidime | – | 0 | 100.0 | 100.0 | 75.0 | 33.3 |
| Cefepime | – | 0 | 100.0 | 100.0 | 75.0 | 66.7 |
| Ciprofloxacin | – | 25.0 | 66.7 | 100.0 | 50.0 | 44.4 |